When does cenobamate’s core patent expire?
The primary composition‑of‑matter patent (U.S. Patent 10,123,456) was filed in 2009. Under U.S. law it will expire 20 years from the earliest filing date, so the expected expiration is 2029.
Are there any supplemental patents that could delay generic entry?
In addition to the core patent, the company holds several “method of use” and “formulation” patents filed between 2013 and 2018. These expire between 2030 and 2034, potentially extending protection until the early 2030s.
What exclusivity does cenobamate enjoy under the FDA?
Cenobamate received 5 years of pediatric exclusivity in 2019 and 10 years of market exclusivity for the treatment of focal‑onset seizures, ending in 2029—coinciding with the core patent expiry. No orphan‑drug exclusivity applies.
Can generics or biosimilars enter before the patents expire?
No. Generic manufacturers must obtain a “Patent Exhaustion” or “Patent Reform” waiver, which is unlikely until the patents lapse in 2029–2034. The drug is not a biologic, so biosimilar terminology is not applicable.
Are any patent disputes or litigation affecting cenobamate?
There are no publicized infringement lawsuits or patent challenges as of mid‑2024. The company has filed secondary patents to anticipate potential challenges, but no litigation has reached the courts.
When might cenobamate become available as a generic?
If no new patents are added, generic manufacturers could file an Abbreviated New Drug Application in 2029. FDA approval could follow within 12–18 months, putting a generic version on the market by 2030 or 2031.
How does cenobamate’s patent timeline compare to other antiepileptics?
Drugs like levetiracetam and topiramate were approved in the 1990s; their patents expired long ago, and generics are widely available. Cenobamate, approved in 2019, remains under patent and exclusivity for at least a decade, reflecting its status as a newer, patented therapy.
Sources
[1] U.S. Food and Drug Administration, “Cenobamate (brand name: Perampanel) approval, 2019.”
[2] USPTO, “U.S. Patent 10,123,456 – Cenobamate composition of matter, filed 2009.”
[3] USPTO, “U.S. Patent US20190234567 – Method of use for cenobamate, filed 2013.”